Prime Medicine, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.6M | $3.0M | $0 | $0 | $0 |
| Operating income | -$208.3M | -$202.5M | -$204.8M | -$116.5M | -$84.5M |
| Operating expenses | $213.0M | $205.4M | $204.8M | $116.5M | $84.5M |
| Cash from operations | -$162.6M | -$122.9M | -$165.4M | -$131.8M | -$34.1M |
| Capital expenditure | $4.5M | $7.3M | $8.7M | $16.1M | $4.2M |
| Free cash flow | -$167.1M | -$130.2M | -$174.1M | -$147.9M | -$38.2M |
| Total assets | $342.7M | $297.5M | $193.9M | $360.3M | $301.9M |
| Total liabilities | $221.9M | $144.4M | $60.8M | $44.0M | $62.3M |
Shares outstanding 180.6M · Free float 64.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.